STAAR Surgical Company (STAA) Receives Outperform Rating with Significant Upside Potential

In a recent rating shift, STAAR Surgical Company (STAA) has been upgraded to “Outperform” by Michael Piccolo of Wedbush on May 14, 2026. This change comes at a crucial juncture for the company, which is currently trading at $29.40, suggesting a substantial upside potential towards the firm’s new price target of $40. For investors keen on exploring opportunities in the medical device sector, this upgrade could signal a noteworthy moment to reassess their positions in STAAR.

Recent Price Action

Trading activity in STAAR has exhibited marked volatility recently. The stock price, currently at $29.40, has experienced a 3.42-point increase, representing an impressive 11.96% surge. The past week has been especially telling, with STAAR’s share price fluctuating between a notable 52-week high of $34.05 and a low of $28.33. Stock volume, critical for assessing investor interest, was a robust 2,333,164 shares, markedly above its average volume of 1,272,409. With a beta of 1.202, STAAR exhibits higher volatility compared to the broader market, indicating its susceptibility to significant price swings. Investors appear to be actively positioning themselves, likely anticipating further growth aligned with the recent analyst optimism.

Historical Performance

Over the past month, STAAR has faced some challenges, reflecting a 19% decline. This downward trend has continued into a quarterly performance drop of 16.22%, and the annual performance has not fared much better, with a decline of 4.05%. However, the stock shows notable weekly volatility at 5.72%, with monthly volatility slightly lower at 5.27%. A closer look at average trading volumes reveals that the 10-day average stands at 800,394, while the 3-month average is slightly higher at 1,281,216, illustrating a fluctuating yet engaged investor interest landscape.

Earnings Analysis

In turn, STAAR’s earnings report has stirred some enthusiasm among investors. The company reported an actual earnings per share (EPS) of $0.19, significantly surpassing the estimated EPS of $0.02794 by an astounding 580.03%. In stark contrast, the previous earnings close on March 3, 2026, had yielded an EPS of -$0.20 against a projection of $0.18, highlighting the current quarter’s financial turnaround. Such a substantial positive earnings surprise indicates a robust operational performance and might enhance investor confidence going forward.

Consensus Ratings

Examining the consensus outlook, STAAR holds a total of seven ratings, with Wedbush’s recent assessment marking the shift to “Outperform.” Among these ratings, two analysts advocate for a “Buy,” while five suggest “Hold,” with no recommendations for “Sell.” The average price target among analysts currently sits at $28.68, with a high price target matching Wedbush’s forecast of $40, and a low of $19. This spectrum of ratings suggests moderate enthusiasm tempered by a cautious stance among investors, pointing to varied levels of confidence regarding STAAR’s capacity to deliver on future performance promises.

Stock Grading or Fundamental View

The Stocks Telegraph Grade, specifically the ST Score for STAAR Surgical Company, is currently at a 40. This score consolidates a comprehensive analysis of the company’s financials and external market conditions. While it emphasizes certain areas for improvement, it also acknowledges the healthcare sector’s growth prospects and STAAR’s innovation potential. Investors looking for quality prospects might find STAAR’s underlying fundamentals appealing, especially in light of its positive earnings surprise and recent upgrade.

Conclusion

For investors considering STAAR Surgical Company, the recent “Outperform” rating and targeted price of $40 present compelling reasons to delve deeper into the stock. While the recent performance trends warrant careful scrutiny, the pronounced turnaround in earnings and overall consensus rating offers a road map for potential:

– **Long-term Growth Investors:** may find STAAR appealing due to its innovation-driven focus within a growing medical device market.
– **Cautious Investors:** must remain aware of volatility and market fluctuations, exemplified by recent performance declines.

The path ahead includes risks, including further fluctuations in performance metrics driven by broader market conditions or internal company challenges. However, with STAAR’s demonstrated potential and the latest analyst endorsement, it stands out as a stock worth monitoring closely.